BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
Levodopa-induced dyskinesias (LIDs) are frequent in parkinsonian patients and may result from an aberrant plasticity. Brain-derived neurotrophic factor (BDNF) represents a likely candidate to subserve neuroadaptive processes encountered in LIDs. We compared striatal BDNF levels measured by ELISA in levodopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared with animals where LIDs were prevented by the addition of CI-1041 (NR1A/2B NMDA receptor antagonist) or low doses of cabergoline (dopamine D2 receptor agonist). We observed reduced striatal BDNF concentrations in levodopa-treated MPTP monkeys with or without LIDs, suggesting that levodopa treatment is associated with reduced striatal BDNF levels and is independent of dyskinesias.
Samadi
Pershia
P
Molecular Endocrinology and Genomic Research Centre, Laval University Medical Centre, Quebec, Canada G1V 4G2.
Morissette
Marc
M
Lévesque
Daniel
D
Di Paolo
Thérèse
T
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001921:Brain / Q000378:metabolism*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism*; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000378:metabolism* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D007980:Levodopa / Q000009:adverse effects*; D020267:MPTP Poisoning / Q000188:drug therapy; D008252:Macaca fascicularis
D000978:Antiparkinson Agents; D019208:Brain-Derived Neurotrophic Factor; D007980:Levodopa